An antigenically diverse, representative panel of envelope glycoproteins for HCV vaccine development

Development of a prophylactic hepatitis C virus (HCV) vaccine will require accurate and reproducible measurement of neutralizing breadth of vaccine-induced antibodies. Currently available HCV panels may not adequately represent the genetic and antigenic diversity of circulating HCV strains, and the lack of standardization of these panels makes it difficult to compare neutralization results obtained in different studies. Here, we describe the selection and validation of a genetically and antigenically diverse reference panel of 15 HCV pseudoparticles (HCVpp) for neutralization assays.

Source: Gastroenterology - October 13, 2021 Category: Gastroenterology Authors: Jordan H. Salas, Richard A. Urbanowicz, Johnathan D. Guest, Nicole Frumento, Alexis Figueroa, Kaitlyn E. Clark, Zhenyong Keck, Vanessa M. Cowton, Sarah J. Cole, Arvind H. Patel, Thomas R. Fuerst, Heidi E. Drummer, Marian Major, Alexander W. Tarr, Jonathan Source Type: research